Thomas Christian Kwee

List of Publications by Year
in descending order

259	6,198	94433 37	88630 70
papers	citations	h-index	g-index

259	259	259	6749
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine, 2018, 24, 1852-1858.	30.7	468
2	Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. European Radiology, 2008, 18, 1937-1952.	4.5	367
3	Chest CT in COVID-19: What the Radiologist Needs to Know. Radiographics, 2020, 40, 1848-1865.	3.3	305
4	Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. European Radiology, 2009, 19, 731-744.	4.5	264
5	Imaging in staging of malignant lymphoma: a systematic review. Blood, 2008, 111, 504-516.	1.4	227
6	Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and freeâ€breathing diffusionâ€weighted MR imaging of the liver. Journal of Magnetic Resonance Imaging, 2008, 28, 1141-1148.	3.4	201
7	FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2122-2132.	6.4	135
8	FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 565-574.	6.4	135
9	Whole-body diffusion-weighted magnetic resonance imaging. European Journal of Radiology, 2009, 70, 409-417.	2.6	133
10	Whole-Body MRI, Including Diffusion-Weighted Imaging, for the Initial Staging of Malignant Lymphoma. Investigative Radiology, 2009, 44, 683-690.	6.2	109
11	FDG PET/CT in carcinoma of unknown primary. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 635-644.	6.4	108
12	ADC measurements of lymph nodes: Inter- and intra-observer reproducibility study and an overview of the literature. European Journal of Radiology, 2010, 75, 215-220.	2.6	104
13	Chest CT Imaging Signature of Coronavirus Disease 2019 Infection. Chest, 2020, 158, 1885-1895.	0.8	97
14	Influence of cardiac motion on diffusion-weighted magnetic resonance imaging of the liver. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2009, 22, 319-325.	2.0	94
15	Complementary Roles of Whole-Body Diffusion-Weighted MRI and¹⁸F-FDG PET: The State of the Art and Potential Applications. Journal of Nuclear Medicine, 2010, 51, 1549-1558.	5.0	92
16	Patientsâ€™ views on the implementation of artificial intelligence in radiology: development and validation of a standardized questionnaire. European Radiology, 2020, 30, 1033-1040.	4.5	88
17	A new dimension of FDG-PET interpretation: assessment of tumor biology. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1158-1170.	6.4	86
18	MR angiography in the follow-up of intracranial aneurysms treated with Guglielmi detachable coils: systematic review and meta-analysis. Neuroradiology, 2007, 49, 703-713.	2.2	78

#	Article	IF	Citations
19	Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Pediatric Radiology, 2010, 40, 1592-1602.	2.0	75
20	Bone marrow ¹⁸Fâ€fluoroâ€2â€deoxyâ€<scp>d</scp>â€glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2014, 89, 726-731.	4.1	70
21	Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis. European Journal of Radiology, 2016, 85, 1963-1970.	2.6	70
22	Systematic review and meta-analysis of MRI signs for diagnosis of idiopathic intracranial hypertension. European Journal of Radiology, 2019, 116, 106-115.	2.6	63
23	Prognostic superiority of the <scp>N</scp>ational <scp>C</scp>omprehensive <scp>C</scp>ancer <scp>N</scp>etwork <scp>I</scp>nternational <scp>P</scp>rognostic <scp>I</scp>ndex over pretreatment wholeâ€body volumetricâ€“metabolic <scp>FDG</scp>â€<scp>PET</scp>/<scp>CT</scp> metrics in diffuse large <scp>B</scp>â€cell lymphoma. European Journal of Haematology, 2015, 94, 532-539.	2.2	58
24	Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation. Seminars in Nuclear Medicine, 2021, 51, 633-645.	4.6	58
25	Prognostic value of complete remission status at endâ€ofâ€treatment FDGâ€PET in Râ€CHOPâ€treated diffuse large Bâ€cell lymphoma: systematic review and metaâ€analysis. British Journal of Haematology, 2015, 170, 185-191.	2.5	57
26	Systematic Review and Meta-Analysis on the Value of Chest CT in the Diagnosis of Coronavirus Disease (COVID-19): Sol Scientiae, Illustra Nos. American Journal of Roentgenology, 2020, 215, 1342-1350.	2.2	55
27	Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Reviews, 2015, 29, 417-425.	5.7	54
28	A Qualitative Study to Understand PatientÂPerspective on the Use of ArtificialÂIntelligenceÂinÂRadiology. Journal of the American College of Radiology, 2019, 16, 1416-1419.	1.8	54
29	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939.	6.4	53
30	Wholeâ€body MRI, including diffusionâ€weighted imaging, for staging lymphoma: Comparison with CT in a prospective multicenter study. Journal of Magnetic Resonance Imaging, 2014, 40, 26-36.	3.4	52
31	Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Annals of Hematology, 2016, 95, 695-706.	1.8	51
32	Prognostic value of interim FDGâ€PET in Hodgkin lymphoma: systematic review and metaâ€analysis. British Journal of Haematology, 2015, 170, 356-366.	2.5	50
33	Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. European Radiology, 2013, 23, 2271-2278.	4.5	44
34	Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis. European Radiology, 2021, 31, 8168-8186.	4.5	44
35	Calcified or ossified benign soft tissue lesions that may simulate malignancy. Skeletal Radiology, 2019, 48, 1875-1890.	2.0	42
36	Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 174-183.	6.4	41

#	Article	IF	Citations
37	Artificial Intelligence in Screening Mammography: A Population Survey of Womenâ€™s Preferences. Journal of the American College of Radiology, 2021, 18, 79-86.	1.8	41
38	Multiparametric MRI and auto-fixed volume of interest-based radiomics signature for clinically significant peripheral zone prostate cancer. European Radiology, 2020, 30, 1313-1324.	4.5	40
39	Role of FDG-PET/CT in children with fever of unknown origin. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1596-1604.	6.4	40
40	Wholeâ€body MRIâ€ĐWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study. Journal of Magnetic Resonance Imaging, 2015, 42, 1646-1655.	3.4	39
41	Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. European Journal of Cancer, 2020, 126, 11-20.	2.8	39
42	SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1475-1477.	6.4	38
43	Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. British Journal of Haematology, 2008, 141, 60-68.	2.5	37
44	Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Annals of Hematology, 2016, 95, 1-9.	1.8	37
45	Workload of diagnostic radiologists in the foreseeable future based on recent scientific advances: growth expectations and role of artificial intelligence. Insights Into Imaging, 2021, 12, 88.	3.4	37
46	Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 106, 55-63.	4.4	33
47	Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Annals of Hematology, 2016, 95, 11-18.	1.8	33
48	Should the ultrasound probe replace your stethoscope? A SICS-I sub-study comparing lung ultrasound and pulmonary auscultation in the critically ill. Critical Care, 2020, 24, 14.	5.8	32
49	Do People Favor Artificial Intelligence Over Physicians? A Survey Among the General Population and Their View on Artificial Intelligence in Medicine. Value in Health, 2022, 25, 374-381.	0.3	32
50	ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphoma: feasibility study. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 1-8.	2.0	31
51	Benign Bone Conditions That May Be FDG-avid and Mimic Malignancy. Seminars in Nuclear Medicine, 2017, 47, 322-351.	4.6	31
52	Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance. European Journal of Haematology, 2015, 95, 83-89.	2.2	30
53	CT-guided biopsy in suspected spondylodiscitis: microbiological yield, impact on antimicrobial treatment, and relationship with outcome. Skeletal Radiology, 2018, 47, 1383-1391.	2.0	30
54	Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma. European Journal of Radiology, 2015, 84, 372-377.	2.6	29

#	Article	IF	Citations
55	Citation advantage for open access articles in European Radiology. European Radiology, 2020, 30, 482-486.	4.5	29
56	Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions. European Radiology, 2021, 31, 875-883.	4.5	28
57	Diagnostic Performance of CO-RADS and the RSNA Classification System in Evaluating COVID-19 at Chest CT: A Meta-Analysis. Radiology: Cardiothoracic Imaging, 2021, 3, e200510.	2.5	27
58	FDG-PET/CT for Detecting an Infection Focus in Patients With Bloodstream Infection. Clinical Nuclear Medicine, 2019, 44, 99-106.	1.3	26
59	Comparison of White Blood Cell Scintigraphy, FDG PET/CT and MRI in Suspected Diabetic Foot Infection: Results of a Large Retrospective Multicenter Study. Journal of Clinical Medicine, 2020, 9, 1645.	2.4	26
60	Ultrasound for diagnosing radiographically occult scaphoid fracture. Skeletal Radiology, 2018, 47, 1205-1212.	2.0	25
61	False positives in PIRADS (V2) 3, 4, and 5 lesions: relationship with reader experience and zonal location. Abdominal Radiology, 2019, 44, 1044-1051.	2.1	25
62	Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging. Investigative Radiology, 2019, 54, 638-644.	6.2	25
63	Can FDG-PET/CT replace blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?. Skeletal Radiology, 2018, 47, 363-367.	2.0	24
64	Diffusion-weighted MR neurography for the assessment of brachial plexopathy in oncological practice. Cancer Imaging, 2015, 15, 6.	2.8	23
65	¹⁸F-FDG PET/CT in Autosomal Dominant Polycystic Kidney Disease Patients with Suspected Cyst Infection. Journal of Nuclear Medicine, 2018, 59, 1734-1741.	5.0	23
66	Wholeâ€body MRI for preventive health screening: A systematic review of the literature. Journal of Magnetic Resonance Imaging, 2019, 50, 1489-1503.	3.4	23
67	Liver fibrosis staging by deep learning: a visual-based explanation of diagnostic decisions of the model. European Radiology, 2021, 31, 9620-9627.	4.5	23
68	Do Not Abandon the Bone Marrow Biopsy Yet in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2015, 33, 1217-1217.	1.6	22
69	Overview of Positron Emission Tomography, Hybrid Positron Emission Tomography Instrumentation, and Positron Emission Tomography Quantification. Journal of Thoracic Imaging, 2013, 28, 4-10.	1.5	21
70	Culture yield of repeat percutaneous image-guided biopsy after a negative initial biopsy in suspected spondylodiscitis: a systematic review. Skeletal Radiology, 2018, 47, 1327-1335.	2.0	21
71	Whole-body MRI vs. CT for staging lymphoma: Patient experience. European Journal of Radiology, 2014, 83, 163-166.	2.6	20
72	Utility of computed diffusionâ€weighted MRI for predicting aggressiveness of prostate cancer. Journal of Magnetic Resonance Imaging, 2017, 46, 490-496.	3.4	20

#	Article	IF	Citations
73	Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?. Acta Radiologica, 2015, 56, 1230-1235.	1.1	19
74	Carbon footprint of the RSNA annual meeting. European Journal of Radiology, 2020, 125, 108869.	2.6	18
75	FDG-PET/CT in intensive care patients with bloodstream infection. Critical Care, 2021, 25, 133.	5.8	18
76	Imaging of Bone Marrow Involvement in Lymphoma: State of the Art and Future Directions. Scientific World Journal, The, 2011, 11, 391-402.	2.1	17
77	Nononcological Applications of Positron Emission Tomography for Evaluation of the Thorax. Journal of Thoracic Imaging, 2013, 28, 25-39.	1.5	17
78	Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 671-679.	0.4	17
79	Diagnostic value of MRI signs in differentiating Ewing sarcoma from osteomyelitis. Acta Radiologica, 2019, 60, 204-212.	1.1	17
80	Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study. European Radiology, 2021, 31, 1494-1504.	4.5	17
81	PET/CT Imaging for Personalized Management of Infectious Diseases. Journal of Personalized Medicine, 2021, 11, 133.	2.5	17
82	Clinical implications of increased uptake in bone marrow and spleen on FDG-PET in patients with bacteremia. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1467-1477.	6.4	16
83	A New Working Paradigm for Radiologists in the Post-COVID-19 World. Journal of the American College of Radiology, 2022, 19, 324-326.	1.8	16
84	Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy. Journal of Magnetic Resonance Imaging, 2014, 39, 1394-1400.	3.4	15
85	Utility of quantitative FDG-PET/CT for the detection of bone marrow involvement in follicular lymphoma: a histopathological correlation study. Skeletal Radiology, 2014, 43, 1231-1236.	2.0	15
86	Tumefactive Virchow-Robin spaces. European Journal of Radiology, 2019, 111, 21-33.	2.6	15
87	The Added Value of [18F]FDG PET/CT in the Management of Invasive Fungal Infections. Diagnostics, 2021, 11, 137.	2.6	15
88	Clinical and Radiologic Predictors of Parastomal Hernia Development After End Colostomy. American Journal of Roentgenology, 2021, 216, 94-103.	2.2	15
89	PET and PET/CT for Unknown Primary Tumors. Methods in Molecular Biology, 2011, 727, 317-333.	0.9	15
90	18F-FDG PET/CT in the Diagnostic and Treatment Evaluation of Pediatric Posttransplant Lymphoproliferative Disorders. Journal of Nuclear Medicine, 2020, 61, 1307-1313.	5.0	15

#	Article	IF	Citations
91	Single-center versus multi-center biparametric MRI radiomics approach for clinically significant peripheral zone prostate cancer. Insights Into Imaging, 2021, 12, 150.	3.4	15
92	Evolving Importance of Diffusion-Weighted Magnetic Resonance Imaging in Lymphoma. PET Clinics, 2012, 7, 73-82.	3.0	14
93	An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. Seminars in Oncology, 2017, 44, 404-419.	2.2	14
94	Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. Lancet Haematology,the, 2020, 7, e479-e489.	4.6	14
95	18F-FDG PET for Diagnosing Infections in Prosthetic Joints. PET Clinics, 2020, 15, 197-205.	3.0	14
96	Coronavirus Disease 2019 and Chest CT: Do Not Put the Sensitivity Value in the Isolation Room and Look Beyond the Numbers. Radiology, 2020, 297, E236-E237.	7.3	13
97	Diffusion-weighted MRI for the detection of colorectal polyps: feasibility study. Magnetic Resonance Imaging, 2013, 31, 28-35.	1.8	12
98	Malignancy rate of biopsied suspicious bone lesions identified on FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1231-1238.	6.4	12
99	The Crisis After the Crisis: The Time Is Now to Prepare Your Radiology Department. Journal of the American College of Radiology, 2020, 17, 749-751.	1.8	12
100	Assessment of Bone Lesions with¹⁸F-FDG PET Compared with^{99m}Tc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management. Journal of Nuclear Medicine, 2021, 62, 177-183.	5.0	12
101	Diagnostic value of computed high b-value wholeâ€body diffusion-weighted imaging for primary prostate cancer. European Journal of Radiology, 2021, 137, 109581.	2.6	12
102	Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1353-1366.	6.4	11
103	Patient complaints in radiology: 9-year experience at a European tertiary care center. European Radiology, 2019, 29, 5395-5402.	4.5	11
104	Dynamic susceptibility MR perfusion in diagnosing recurrent brain metastases after radiotherapy: A systematic review and metaâ€analysis. Journal of Magnetic Resonance Imaging, 2020, 51, 524-534.	3.4	11
105	A deep learning masked segmentation alternative to manual segmentation in biparametric MRI prostate cancer radiomics. European Radiology, 2022, 32, 6526-6535.	4.5	11
106	Diffusion-weighted MRI for detecting liver metastases: importance of the b-value. European Radiology, 2011, 21, 150-150.	4.5	10
107	Oncological Applications of Positron Emission Tomography for Evaluation of the Thorax. Journal of Thoracic Imaging, 2013, 28, 11-24.	1.5	10
108	Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphoma. European Journal of Radiology, 2016, 85, 304-309.	2.6	10

#	Article	IF	Citations
109	Controversies on the prognostic value of interim <scp>FDG</scp>â€<scp>PET</scp> in advancedâ€stage Hodgkin lymphoma. European Journal of Haematology, 2016, 97, 491-498.	2.2	10
110	Which patients are prone to undergo disproportionate recurrent CT imaging and should we worry?. European Journal of Radiology, 2020, 125, 108898.	2.6	10
111	Whole-body MRI versus an [18F]FDG-PET/CT-based reference standard for early response assessment and restaging of paediatric Hodgkinâ€™s lymphoma: a prospective multicentre study. European Radiology, 2021, 31, 8925-8936.	4.5	10
112	Diagnostic performance of MRI and CT in diagnosing necrotizing soft tissue infection: a systematic review. Skeletal Radiology, 2022, 51, 727-736.	2.0	10
113	Communication and empathy skills: Essential requisites for patient-centered radiology care. European Journal of Radiology, 2021, 140, 109754.	2.6	10
114	Gender diversity among editorial boards of radiology-related journals. Clinical Imaging, 2021, 75, 30-33.	1.5	10
115	Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 231-8.	1.0	10
116	Increased bone marrow <scp>FDG</scp> uptake at <scp>PET</scp>/<scp>CT</scp> is not a sufficient proof of bone marrow involvement in diffuse large <scp>B</scp>â€cell lymphoma. American Journal of Hematology, 2015, 90, E182-3.	4.1	9
117	Fabella Fractures after Total Knee Arthroplasty with Correction of Valgus Malalignment. Case Reports in Orthopedics, 2016, 2016, 1-5.	0.3	9
118	Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 141, 73-81.	4.4	9
119	Combining Hepatic and Splenic CT Radiomic Features Improves Radiomic Analysis Performance for Liver Fibrosis Staging. Diagnostics, 2022, 12, 550.	2.6	9
120	Diffusion-weighted whole-body imaging with background body signal suppression facilitates detection and evaluation of an anterior rib contusion. Clinical Imaging, 2010, 34, 298-301.	1.5	8
121	Successful conservative management of symptomatic bilateral dorsal patellar defects presenting with cartilage involvement and bone marrow edema: MRI findings. Skeletal Radiology, 2016, 45, 723-727.	2.0	8
122	Overestimated Value of Baseline Total Metabolic Tumor Volume at 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography in Follicular Lymphoma. Journal of Clinical Oncology, 2017, 35, 918-919.	1.6	8
123	Surveillance MRI for the detection of locally recurrent Ewing sarcoma seems futile. Skeletal Radiology, 2018, 47, 1517-1522.	2.0	8
124	The new integrated nuclear medicine and radiology residency program in the Netherlands: why do residents choose to subspecialize in nuclear medicine and why not?. Journal of Nuclear Medicine, 2021, 62, jnumed.120.261503.	5.0	8
125	Outcome of Hodgkin Lymphoma Patients With a Posttreatment¹⁸F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)â€“Negative Residual Mass: Systematic Review and Meta-analysis. Pediatric Hematology and Oncology, 2015, 32, 515-524.	0.8	7
126	Both Interim and End-of-Treatment ¹⁸F-Fluoro-2-Deoxy-<scp>d</scp>-Glucose Positron Emission Tomography Scans Have Low Value in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2016, 34, 765-766.	1.6	7

#	Article	IF	Citations
127	Lymphoma grading with FDG-PET/CT readdressed: Direct and timely histopathological correlation study. Acta OncolÃ³gica, 2016, 55, 386-390.	1.8	7
128	Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis. Clinical Sarcoma Research, 2018, 8, 16.	2.3	7
129	Repeatability analysis of ADC histogram metrics of the uterus. Acta Radiologica, 2019, 60, 526-534.	1.1	7
130	FDG-avid presacral soft tissue mass in previously treated rectal cancer: Diagnostic outcome and additional value of MRI, including diffusion-weighted imaging. European Journal of Surgical Oncology, 2019, 45, 606-612.	1.0	7
131	Systematic review on the value of end-of-treatment FDG-PET in improving overall survival of lymphoma patients. Annals of Hematology, 2020, 99, 1-5.	1.8	7
132	Medical disciplinary jurisprudence in alleged malpractice in radiology: 10-year Dutch experience. European Radiology, 2020, 30, 3507-3515.	4.5	7
133	Patient safety incidents in radiology: frequency and distribution of incident types. Acta Radiologica, 2021, 62, 653-666.	1.1	7
134	MRI after Whoops procedure: diagnostic value for residual sarcoma and predictive value for an incomplete second resection. Skeletal Radiology, 2021, 50, 2213-2220.	2.0	7
135	Imaging of facet joint diseases. Clinical Imaging, 2021, 80, 167-179.	1.5	7
136	Diagnostic performance of MRI in detecting locally recurrent soft tissue sarcoma: systematic review and meta-analysis. European Radiology, 2022, 32, 3915-3930.	4.5	7
137	MRI for staging lymphoma: Wholeâ€body or less?. Journal of Magnetic Resonance Imaging, 2011, 33, 1144-1150.	3.4	6
138	Can whole-body MRI replace 18F-fluorodeoxyglucose PET/CT?. Lancet Oncology, The, 2014, 15, 243-244.	10.7	6
139	Should the nuclear medicine community continue to underestimate the potential of 18F-FDG-PET/CT with present generation scanners for the diagnosis of prosthetic joint infection?. Nuclear Medicine Communications, 2015, 36, 756-757.	1.1	6
140	Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects. Acta Radiologica, 2016, 57, 733-741.	1.1	6
141	Predictive Value of Interim [18F]Fluorodeoxyglucoseâ€“Positron Emission Tomography in Advanced-Stage Hodgkin Lymphoma Is Not Well Established. Journal of Clinical Oncology, 2017, 35, 370-371.	1.6	6
142	Pretransplant <scp>FDG</scp>â€<scp>PET</scp> in aggressive nonâ€Hodgkin lymphoma: systematic review and metaâ€analysis. European Journal of Haematology, 2017, 98, 337-347.	2.2	6
143	Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements. European Radiology, 2019, 29, 6018-6028.	4.5	6
144	Funding of Radiology Research: Frequency and Association With Citation Rate. American Journal of Roentgenology, 2020, 215, 1286-1289.	2.2	6

#	Article	IF	Citations
145	Unread Second-Opinion Radiology Reports: A Potential Waste of Health Care Resources. American Journal of Roentgenology, 2020, 215, 934-939.	2.2	6
146	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1522-1537.	6.4	6
147	Peer review practices by medical imaging journals. Insights Into Imaging, 2020, 11, 125.	3.4	6
148	Apparent diffusion coefficient measurement in a moving phantom simulating linear respiratory motion. Japanese Journal of Radiology, 2010, 28, 578-583.	2.4	5
149	Wholeâ€body MRI for staging Hodgkin lymphoma in a pregnant patient. American Journal of Hematology, 2010, 85, 443-443.	4.1	5
150	Whole-body MRI for Detecting Bone Marrow Metastases. PET Clinics, 2010, 5, 297-309.	3.0	5
151	Primary tumor volume measurements in Ewing sarcoma: MRI inter- and intraobserver variability and comparison with FDG-PET. Acta OncolÃ³gica, 2018, 57, 534-540.	1.8	5
152	Radiofrequency ablation of atypical cartilaginous tumors in long bones: a retrospective study. International Journal of Hyperthermia, 2019, 36, 1189-1195.	2.5	5
153	Radiofrequency ablation in the treatment of atypical cartilaginous tumours in the long bones: lessons learned from our experience. Skeletal Radiology, 2019, 48, 881-887.	2.0	5
154	Recommendations for additional imaging of abdominal imaging examinations: frequency, benefit, and cost. European Radiology, 2020, 30, 1137-1144.	4.5	5
155	Point-of-care ultrasound (POCUS): An opportunity for radiologists to improve patient care?. European Journal of Radiology, 2021, 139, 109690.	2.6	5
156	Diagnostic value of texture analysis of apparent diffusion coefficient maps for differentiating fat-poor angiomyolipoma from non-clear-cell renal cell carcinoma. European Journal of Radiology, 2021, 143, 109895.	2.6	5
157	Role of Structural Imaging in Lymphoma. PET Clinics, 2012, 7, 1-19.	3.0	4
158	Prognostic Implications of Imaging-Based Bone Marrow Assessment in Lymphoma: ¹⁸F-FDG PET, MR Imaging, or ¹⁸F-FDG PET/MR Imaging?. Journal of Nuclear Medicine, 2013, 54, 2017-2018.	5.0	4
159	CT-Based Versus FDG-PET/CTâ€“Based NCCN International Prognostic Index Risk Stratification in DLBCL. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 171-176.	4.9	4
160	Falseâ€negative <scp>FDG</scp>â€<scp>PET</scp> in histologically proven extensive large cell bone marrow involvement in diffuse large <scp>B</scp>â€cell lymphoma. American Journal of Hematology, 2015, 90, 681-681.	4.1	4
161	Will treatment intensification in early-stage Hodgkin lymphoma patients with a positive interim FDG-PET improve outcome?. Pediatric Hematology and Oncology, 2016, 33, 1-4.	0.8	4
162	Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma. Lancet Haematology,the, 2017, 4, e63-e64.	4.6	4

#	Article	IF	Citations
163	Debate on the value of end-of-treatment FDG-PET response evaluation in follicular lymphoma. Acta OncolÃ³gica, 2017, 56, 1789-1791.	1.8	4
164	Does endâ€ofâ€treatment <scp>FDG</scp>â€<scp>PET</scp> provide any additional prognostic value to the preâ€treatment <scp>NCCN</scp>â€<scp>IPI</scp> score?. British Journal of Haematology, 2017, 177, 319-320.	2.5	4
165	Interim Fluorodeoxyglucose Positron Emission Tomographyâ€“Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma. Journal of Clinical Oncology, 2017, 35, 2850-2851.	1.6	4
166	The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population. Skeletal Radiology, 2020, 49, 1387-1395.	2.0	4
167	Carbon footprint of air travel to international radiology conferences: FOMO?. European Radiology, 2020, 30, 6293-6294.	4.5	4
168	Effects of control temperature, ablation time, and background tissue in radiofrequency ablation of osteoid osteoma: A computer modeling study. International Journal for Numerical Methods in Biomedical Engineering, 2021, 37, e3512.	2.1	4
169	Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [18F]FDG PET/CT. Journal of Clinical Medicine, 2021, 10, 361.	2.4	4
170	Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements. European Journal of Radiology Open, 2022, 9, 100403.	1.6	4
171	Improving background suppression in diffusion-weighted imaging of the abdomen and pelvis using STIR with single-axis diffusion encoding. Magnetic Resonance Imaging, 2011, 29, 877-880.	1.8	3
172	Potential Clinical Applications of PET/Magnetic Resonance Imaging. PET Clinics, 2013, 8, 367-384.	3.0	3
173	Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?. American Journal of Hematology, 2016, 91, E1-E2.	4.1	3
174	18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains. Nuclear Medicine Communications, 2016, 37, 333-337.	1.1	3
175	Radiation-Induced Giant Cell Granuloma Mimicking Relapsed Hodgkin Lymphoma at FDG-PET/CT. Nuclear Medicine and Molecular Imaging, 2017, 51, 371-373.	1.0	3
176	Overestimated value of <scp>FDG</scp>â€<scp>PET</scp> based bone marrow evaluation in lymphoma. British Journal of Haematology, 2017, 179, 336-337.	2.5	3
177	Interim FDG-PET/CT in Hodgkin lymphoma: what are we actually looking at?. Acta OncolÃ³gica, 2018, 57, 1128-1130.	1.8	3
178	Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 226.2-228.	4.9	3
179	Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomographyâ€“Adapted Treatment in Advanced-Stage Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 2123-2124.	1.6	3
180	Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been proven. Blood, 2018, 132, 339-340.	1.4	3

#	Article	IF	Citations
181	JOURNAL CLUB: CT-Guided Bone Biopsies With Indeterminate Results in Pediatric Patients. American Journal of Roentgenology, 2018, 211, 661-671.	2.2	3
182	Recommendations in Clinical 18F-Fluoro-2-Deoxy-D-Glucose PET/CT Reports: Referring Physiciansâ€™ Compliance and Diagnostic Yield. Journal of the American College of Radiology, 2018, 15, 1269-1275.	1.8	3
183	Canceled or aborted CT-guided interventions: 13-year clinical experience at a tertiary care center. European Radiology, 2019, 29, 3372-3378.	4.5	3
184	Interim FDGâ€PET does not predict outcome in advancedâ€stage Hodgkin lymphoma patients treated with BEACOPP. British Journal of Haematology, 2019, 185, 758-760.	2.5	3
185	Improved Visualization of Middle Ear Cholesteatoma with Computed Diffusion-weighted Imaging. Magnetic Resonance in Medical Sciences, 2019, 18, 233-237.	2.0	3
186	Recommendations in Second Opinion Radiology Reports of Abdominal Imaging Examinations: Referring Clinicians' Compliance and Diagnostic Outcome. American Journal of Roentgenology, 2020, 214, 400-405.	2.2	3
187	Diagnostic errors in clinical FDG-PET/CT. European Journal of Radiology, 2020, 132, 109296.	2.6	3
188	A new complication registration system for errors in radiology: Initial 5-year experience in a tertiary care radiology department. European Journal of Radiology, 2020, 130, 109167.	2.6	3
189	Towards a benchmark of abdominal CT use during duty shifts: 15-year sample from the Netherlands. Abdominal Radiology, 2021, 46, 1761-1767.	2.1	3
190	Funding of nuclear medicine research and association with citation impact. Clinical and Translational Imaging, 2021, 9, 123-127.	2.1	3
191	Clinical and FDG-PET/CT Suspicion of Malignant Disease: Is Biopsy Confirmation Still Necessary?. Diagnostics, 2021, 11, 559.	2.6	3
192	Assessment of hepatic artery anatomy in pediatric liver transplant recipients: MR angiography versus CT angiography. Pediatric Transplantation, 2021, 25, e14002.	1.0	3
193	Medical knowledge and clinical productivity: independently correlated metrics during radiology residency. European Radiology, 2021, 31, 5344-5350.	4.5	3
194	Maintenance of certification for radiologists: an overview of European countries. Insights Into Imaging, 2020, 11, 85.	3.4	3
195	Health Care Industry Payments to Editorial Board Members of Imaging-related Journals. Radiology, 2022, 303, 399-403.	7.3	3
196	Clinical utility of the Bosniak classification version 2019: Diagnostic value of adding magnetic resonance imaging to computed tomography examination. European Journal of Radiology, 2022, 148, 110163.	2.6	3
197	The integrated nuclear medicine and radiology residency program in the Netherlands: strengths and potential areas for improvement according to nuclear medicine physicians and radiologists. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3016-3022.	6.4	3
198	Incidental imaging findings referred to a specialized sarcoma center: Frequency, determinants, and downstream healthcare costs. Clinical Imaging, 2022, 85, 99-105.	1.5	3

#	Article	IF	Citations
199	Knee radiography in the diagnosis of skeletal dysplasias. Pediatric Radiology, 2005, 36, 8-15.	2.0	2
200	Application of Advanced MR Imaging Techniques and the Evolving Role of PET/MR Imaging in Neuro-oncology. PET Clinics, 2013, 8, 183-199.	3.0	2
201	Critical considerations on the utility of ¹⁸Fâ€fluoroâ€2â€deoxyâ€Dâ€glucose positron emission tomography/computed tomography for posttreatment restaging of the bone marrow in diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2014, 89, 935-935.	4.1	2
202	In Regard to Simontacchi et al. International Journal of Radiation Oncology Biology Physics, 2015, 93, 724-725.	0.8	2
203	Diffusion-Weighted MRI for Lymphoma Stagingâ€"Letter. Clinical Cancer Research, 2015, 21, 221-221.	7.0	2
204	Seriously overestimated prognostic value of baseline and interim FDG-PET in diffuse large B cell lymphoma. Annals of Hematology, 2016, 95, 1367-1368.	1.8	2
205	No convincing evidence to support postinduction FDG-PET in follicular lymphoma. Annals of Hematology, 2016, 95, 2085-2086.	1.8	2
206	Effect of blind bone marrow biopsy on FDG-PET/CT interpretation of the posterior iliac crest in diffuse large B-cell lymphoma. Hematological Oncology, 2016, 34, 52-54.	1.7	2
207	In Regard to Ceriani etÂal. International Journal of Radiation Oncology Biology Physics, 2017, 97, 869-870.	0.8	2
208	Interim FDG-PET in lymphoma, a questionable practice in hematology. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2014-2017.	6.4	2
209	The Deauville criteria cannot differentiate between responding and non-responding non-Hodgkin lymphoma patients. Annals of Hematology, 2018, 97, 719-720.	1.8	2
210	Interim <scp>FDG</scp>â€<scp>PET</scp> has no value in selecting patients who require treatment modification in both earlyâ€•and advancedâ€stage Hodgkin lymphoma. British Journal of Haematology, 2018, 183, 129-131.	2.5	2
211	Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma. Haematologica, 2018, 103, e380-e381.	3.5	2
212	Value of detecting bone marrow involvement in Hodgkin lymphoma. British Journal of Haematology, 2019, 187, 397-399.	2.5	2
213	The diagnostic significance of repeat ultrasound-guided biopsy of musculoskeletal soft-tissue lesions with initially inconclusive biopsy results. European Journal of Surgical Oncology, 2019, 45, 1266-1273.	1.0	2
214	A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma. Journal of Clinical Oncology, 2019, 37, 852-853.	1.6	2
215	Postâ€<scp>ABVD</scp> biopsy results, and not postâ€<scp>ABVD FDG</scp>â€<scp>PET</scp> results, predict outcome in earlyâ€stage Hodgkin lymphoma. British Journal of Haematology, 2019, 184, 290-292.	2.5	2
216	Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?. Cancer Treatment Reviews, 2020, 87, 102027.	7.7	2

#	Article	IF	Citations
217	Chest CT in Patients with COVID-19: Toward a Better Appreciation of Study Results and Clinical Applicability. Radiology, 2021, 298, E113-E114.	7.3	2
218	Time to Reconsider Routine Percutaneous Biopsy in Spondylodiscitis?. American Journal of Neuroradiology, 2021, 42, 627-631.	2.4	2
219	Requests for radiologic imaging: Prevalence and determinants of inadequate quality according to RI-RADS. European Journal of Radiology, 2021, 137, 109615.	2.6	2
220	Radiologist-patient consultation of imaging findings after neck ultrasonography: An opportunity to practice value-based radiology. Clinical Imaging, 2022, 81, 87-91.	1.5	2
221	Diagnostic performance of MRI in detecting residual soft tissue sarcoma after unplanned excision: Systematic review and meta-analysis. European Journal of Radiology, 2021, 145, 110049.	2.6	2
222	Value-based radiology cannot thrive without reforms and research. European Radiology, 2022, 32, 4337-4339.	4.5	2
223	PET Assessment of Brown Fat. PET Clinics, 2011, 6, 365-375.	3.0	1
224	Evolving Medical Imaging Techniques. PET Clinics, 2013, 8, xi-xii.	3.0	1
225	Suboptimal use of imaging in the new (National Comprehensive Cancer Network) International Prognostic Index for diffuse large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 806-807.	6.4	1
226	Diffusion-Weighted MRI for Lymphoma Restagingâ€"Letter. Clinical Cancer Research, 2015, 21, 3808-3808.	7.0	1
227	Assessing baseline bone marrow status in advanced-stage Hodgkin lymphoma: does it have any purpose?. Annals of Hematology, 2017, 96, 1047-1048.	1.8	1
228	Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1934-1936.	6.4	1
229	Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 342-343.	6.4	1
230	The Diabetic Foot. Current Pharmaceutical Design, 2018, 24, 1241-1242.	1.9	1
231	A Pitfall for Diffusion-weighted MR Imaging When Assessing the Response to Neoadjuvant Chemotherapy in Ewing Sarcoma. Magnetic Resonance in Medical Sciences, 2019, 18, 249-250.	2.0	1
232	Standardized Definition of Progression-Free Survival in Diffuse Large B-Cell Lymphoma Is Urgently Needed. Journal of Clinical Oncology, 2019, 37, 525-526.	1.6	1
233	Frequency, Determinants, and Costs of Recommendations for Additional Imaging in Clinical ¹⁸F-FDG PET/CT Reports. Journal of Nuclear Medicine, 2019, 60, 1228-1233.	5.0	1
234	Inability of Fluorodeoxyglucose Positron Emission Tomography to Detect Viable Hodgkin Lymphoma During and After Treatment. Journal of Clinical Oncology, 2020, 38, 1115-1116.	1.6	1

#	Article	IF	Citations
235	Research Output by Medical Doctors After PhD Graduation in Radiology: 17-Year Experience From the Netherlands. Academic Radiology, 2021, 28, 827-833.	2.5	1
236	Long-Term Halo Follow-Up Confirms Less Invasive Treatment of Low-Grade Cartilaginous Tumors with Radiofrequency Ablation to Be Safe and Effective. Journal of Clinical Medicine, 2021, 10, 1817.	2.4	1
237	Computer 3D modeling of radiofrequency ablation of atypical cartilaginous tumours in long bones using finite element methods and real patient anatomy. European Radiology Experimental, 2022, 6, 21.	3.4	1
238	PET and PET/CT Assessment of Gynecologic Malignancies: Beyond FDG. PET Clinics, 2010, 5, 477-482.	3.0	0
239	A ruptured intracranial aneurysm with underlying cervicocranial fibromuscular dysplasia. Vascular Medicine, 2012, 17, 66-67.	1.5	0
240	Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCLâ€”Letter. Clinical Cancer Research, 2016, 22, 3413-3413.	7.0	0
241	End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphoma. Annals of Hematology, 2016, 95, 2083-2084.	1.8	0
242	Guest Editorial on PET of Benign Musculoskeletal Conditions. Seminars in Nuclear Medicine, 2017, 47, 320-321.	4.6	0
243	Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma. Annals of Hematology, 2018, 97, 915-916.	1.8	0
244	Macrodactyly with a complex glomuvenous malformation in congenital lipomatous overgrowth with vascular malformations, epidermal naevi and skeletal anomalies (<scp>CLOVES</scp>) syndrome. Histopathology, 2018, 73, 705-708.	2.9	0
245	Predictive gene-expression score for follicular lymphoma. Lancet Oncology, The, 2018, 19, e280.	10.7	0
246	Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma?. Lancet Oncology, The, 2019, 20, e4.	10.7	0
247	Assessing complete remission status in incurable follicular lymphomas, to what purpose?. British Journal of Haematology, 2019, 184, 467-469.	2.5	0
248	Are Researchers Willing to Share Their Published Manuscript?. Science and Engineering Ethics, 2020, 26, 121-122.	2.9	0
249	Dealing with a soft tissue lesion that is scheduled for CT-guided biopsy and that has decreased in size on preprocedural planning CT. BJR|case Reports, 2020, 6, 20190071.	0.2	0
250	Starting as a Newly Graduated Radiologist: Survival Tips From Experience Experts. Journal of the American College of Radiology, 2021, 18, 1009-1011.	1.8	0
251	Response. Chest, 2021, 159, 2108.	0.8	0
252	Reply to â€œAdditional Issues to Consider in Radiology Researchâ€• American Journal of Roentgenology, 2021, 216, W24-W24.	2.2	0

#	Article	IF	Citations
253	Recommendations in Second Opinion Reports of Neurologic Head and Neck Imaging: Frequency, Referring Cliniciansâ€™ Compliance, and Diagnostic Yield. American Journal of Neuroradiology, 2021, 42, 1676-1682.	2.4	0
254	Radiologist-patient communication of musculoskeletal ultrasonography results: a choice between added value and costs. Acta Radiologica, 2024, 65, 267-272.	1.1	0
255	Predictive value of a false-negative focused abdominal sonography for trauma (FAST) result in patients with confirmed traumatic abdominal injury. Insights Into Imaging, 2020, 11, 102.	3.4	0
256	Elevate value in neck ultrasonography to a next level. Clinical Imaging, 2022, , .	1.5	0
257	Mapping the cancer imaging research landscape: which cancers are more and which cancers are less frequently investigated?. Clinical Imaging, 2022, 85, 89-93.	1.5	0
258	On-call abdominal ultrasonography: the rate of negative examinations and incidentalomas in a European tertiary care center. Abdominal Radiology, 2022, , 1.	2.1	0
259	Point-of-care ultrasonography: Downstream utilization of and diagnostic (dis)agreements with additional cross-sectional imaging. European Journal of Radiology, 2022, 152, 110344.	2.6	0